MediGene Pads Coffers, Inks $17.7M Eligard Royalty Deal
By Marie Powers
Friday, June 8, 2012
MediGene AG became the latest biotech to choose a royalty deal over other financing options to bolster its bottom line. The company transferred its 2 percent royalty share of European net sales in prostate cancer drug Eligard (leuprolide acetate) to Cowen Healthcare Royalty Partners II LP for $17.7 million in cash.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.